Shots:

• The study enrolled BADBIR-registered patient treated with Benepali from Jan 01- 2016 to Sept 01- 2018. BADBIR is a UK and Ireland observational study assessing long-term safety of biologic treatments for psoriasis while Samsung Bioepis participated in it since May 2016
• The mean disease duration was 22.6 yrs.- PASI and DLQI scores 11.6 and 13.1 respectively- median treatment period 14.1 months. In 48 patients with PASI score at baseline and 6 mos. PASI < 10 (N=20- mean PASI 3.2) no increment after 6 mos. and PASI ≥ 10 (N=28- mean PASI 15.7) reduced after 6 mos. (mean PASI 5.0)
• Benepali (biosimilar- etanercept) referencing Enbrel is an anti-TNF biosimilar approved by EC in Jan 2016- for moderate to severe RA- JIA- PsA- axSpA  (ankylosing spondylitis and non-radiographic axial spondyloarthritis)- and plaque psoriasis and is available in 25 countries in EU plus most prescribed across France- Germany- Italy- Spain- and the UK combined

Click here to­ read full press release/ article 

 Ref: Samsung Bioepis | Image: Samsung Bioepis